



Axonics® to Present at Upcoming Investor Conferences

May 4, 2020

IRVINE, Calif.--(BUSINESS WIRE)--May 4, 2020-- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation ("SNM") devices for the treatment of urinary and bowel dysfunction, announced today that members of the senior management team will present at the following upcoming investor conferences and will be available for meetings with institutional investors:

Raymond W. Cohen, Chief Executive Officer, is scheduled for a fireside chat at the SunTrust Robinson Humphrey Life Sciences Virtual Meeting Series on Wednesday, May 6, at 11:00 am ET.

Cohen is also scheduled for a fireside chat at the BofA Securities Health Care Conference on Wednesday, May 13, at 1:40 pm ET.

To access the live webcast of the fireside chats at the aforementioned conferences, please visit the Events & Presentations page of the Investor Relations section of the Axonics website at ir.axonics.com. A replay of the webcasts will be available shortly after the conclusion of the fireside chats and will be archived on the Axonics website for 90 days.

About Axonics Modulation Technologies, Inc.

Axonics, based in Irvine, Calif., has developed and is commercializing novel implantable SNM devices for patients with urinary and bowel dysfunction. These conditions are caused by a miscommunication between the bladder and the brain and significantly impact quality of life. Overactive bladder affects an estimated 87 million adults in the U.S. and Europe. Another estimated 40 million adults are reported to suffer from fecal incontinence/accidental bowel leakage. SNM therapy has been employed to reduce symptoms and restore pelvic floor function for the past two decades. Reimbursement coverage is well established in the U.S. and Europe. The Axonics System is the first long-lived rechargeable SNM system approved for sale in the world, and the first to gain full-body MRI conditional labeling. For more information, visit the Company's website at www.axonics.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20200504005076/en/): <https://www.businesswire.com/news/home/20200504005076/en/>

Axonics contact:

Neil Bhalodkar
Investor Relations
949-336-5293
ir@axonics.com

Source: Axonics